Abstract Pain remains highly prevalent in HIV-seropositive (HIV+) patients despite their well-suppressed viremia with combined antiretroviral therapy. Investigating brain abnormalities within the pain matrix, and in relation to pain symptoms, in HIV+ participants may provide objective biomarkers and insights regarding their pain symptoms. We used PatientReported Outcome Measurement Information System (PROMIS®) pain questionnaire to evaluate pain symptoms (pain intensity, pain interference and pain behavior), and structural MRI to assess brain morphometry using FreeSurfer (cortical area, cortical thickness and subcortical volumes were evaluated in 12 regions within the pain matrix). Compared to seronegative (SN) controls, HIV+ participants had smaller surface areas in prefrontal pars triangularis (right: p = 0.04, left: p = 0.007) and right anterior cingulate cortex (p = 0.03) and smaller subcortical regions (thalamus: p ≤ 0.003 bilaterally; right putamen: p = 0.01), as well as higher pain scores (pain intensityp = 0.005; pain interference-p = 0.008; pain-behavior-p = 0.04). Furthermore, higher pain scores were associated with larger cortical areas, thinner cortices and larger subcortical volumes in HIV+ participants; but smaller cortical areas, thicker cortices and smaller subcortical volumes in SN controls (interactionp = 0.009 to p = 0.04). These group differences in the painassociated brain abnormalities suggest that HIV+ individuals have abnormal pain responses. Since these abnormal painassociated brain regions belong to the affective component of the pain matrix, affective symptoms may influence pain perception in HIV+ patients and should be treated along with their physical pain symptoms. Lastly, associations of lower pain scores with better physical or mental health scores, regardless of HIV-serostatus (p < 0.001), suggest adequate pain treatment would lead to better quality of life in all participants.
Introduction
Pain is one of the most common self-reported symptoms in HIV-seropositive (HIV+) individuals (Lawson et al. 2014; Uebelacker et al. 2015) . Assessing pain symptoms in HIV+ individuals can be challenging since pain is highly subjective, which may lead to under-treatment of their pain symptoms. Additionally, opioids are often prescribed for pain management in HIV patients, which is risky for those who are coprescribed sedative medications (Merlin 2015) . Furthermore, opioids could potentiate HIV disease progression (Zou et al. 2011; Liu et al. 2016) , and have high propensity for drug dependence (Krashin et al. 2012) . Understanding whether brain abnormalities in HIV patients might be related to their subjective pain symptoms may provide insights for their pain management. Recent studies showed brain morphologic abnormalities in patients with chronic pain disorders (Baliki et al. 2011) , such as fibromyalgia, chronic back pain, irritable bowel syndrome or neuropathic pain (Schmidt-Wilcke 2015) . Brain regions shown to be abnormal in patients with chronic Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11481-017-9762-5) contains supplementary material, which is available to authorized users.
pain were grouped as the Bpain matrix^ (Fig. 1) , which involves more than direct physical pain, but primarily for nociceptive processing and pain modulation (Bushnell et al. 1999; Melzack 2005; Iannetti et al. 2013) . However, whether alterations in brain structures within the pain matrix is related to subjective pain symptoms in HIV patients is unknown, and were investigated in the present study.
We explored the neuroimaging signature for pain in HIV+ individuals by evaluating the relationships between morphometric abnormalities within the pain matrix on brain MRI, and selfreported pain symptoms assessed with National Institute of Health (NIH) Toolbox Patient Reported Outcome Measurement Information System (PROMIS®) pain questionnaire (Amtmann et al. 2010; Cella et al. 2010) . Specifically, we aimed to: (1) assess HIV+ individuals on self-reported pain intensity, pain interference and pain behavior; (2) identify brain regions within the pain matrix that show brain abnormalities in HIV+ individuals compared to HIV-seronegative (SN) controls; (3) compare the relationships between these abnormal cortical and subcortical morphometric measures and pain severity in ambulatory HIV+ individuals and in SN controls; and (4) determine the relationships between the pain severity and mental or physical health in HIV+ and SN individuals.
Based on prior studies, we propose the following hypotheses: (1) Since weakened immune system caused by HIV infection may lead to higher risk for painful co-morbidities (Lawson et al. 2014) , HIV+ individuals will have higher pain intensity, pain interference and pain behavior scores than SN controls. (2) Brain atrophy may result from chronic neuroinflammation in both HIV-associated brain injury (Gray et al. 2001; Chang et al. 2011 ) and chronic pain (Apkarian and Scholz 2006; Moayedi et al. 2012) . Therefore, compared to SN controls, HIV+ individuals, especially those with pain symptoms, are expected to show smaller cortical areas, thinner cortices and smaller subcortical brain volumes within the pain matrix. (3) Since greater pain symptoms were associated with more gray matter atrophy both in HIV+ individuals (Keltner et al. 2014) and within the pain matrix in patients with chronic back pain (Fritz et al. 2016) , we hypothesize that all participants with greater pain symptoms will have smaller volumes or thinner cortices within the pain matrix. However, this inverse relationship may be more pronounced in HIV+ individuals than SN controls due to the greater neuroinflammation (Gray et al. 2001; Chang et al. 2014) . (4) Individuals with chronic pain and HIV+ patients with pain symptoms both had poorer mental and physical health compared to individuals without pain (Breitbart et al. 1996; Merlin et al. 2013; Uebelacker et al. 2015; Mann et al. 2016) ; therefore, greater pain severity will be associated with poorer mental health and physical health scores in both HIV+ and SN individuals. (Apkarian et al. 2005; Melzack 2005; Tracey and Mantyh 2007; Schweinhardt and Bushnell 2010; Oertel et al. 2012; Hashmi et al. 2013; Atlas et al. 2014) . The pain matrix comprises regions involved in pain processing and pain modulation. These brain regions are grouped into 3 different pain components: sensory or discriminative, affective and associative, which are all interconnected to each other. The sensory or discriminative component comprised mainly of the thalamus (Thal) and the somatosensory cortex (SSC) The affective component includes the brainstem, Thal, the limbic system [amygdala, hippocampus, basal ganglia (BG)], prefrontal cortex (PFC), anterior cingulate cortex (ACC) and, insula (IN). The associative component includes the posterior parietal cortex (PPC). The regions surrounded with white halo are the regions of interest selected for the current study
Materials and Methods
Participants A total 106 participants were screened and were randomly but consecutively chosen from 206 participants who were being enrolled in a larger neuroimaging study of brain changes after cognitive training (Chang et al. 2016 (Chang et al. , 2017 . However, 66 (31 HIV+ and 35 SN) of these participants agreed to be co-enrolled in the current study to evaluate the neuroimaging signature of pain (between June 20th 2013 to December 15th, 2015.) The study design, experiments and consent forms were approved by the Cooperative Institutional Review Board of the University of Hawaíi at Mānoa, CHS#20523.
The participants were initially recruited through flyers, referrals from the local community and clinics, or by word-ofmouth. They were screened first by telephone or in person. Potentially qualified participants provided informed consent and signed the approved consent form before under-going further detailed evaluations, including review of the medical records by a study physician to ensure they fulfilled all study criteria. The inclusion criteria for all participants were: (1) men or women of any ethnicity, ages ≥ 18 years; (2) able to provide informed consent, with a minimum of an 8th grade reading level (verified by the Wechsler Test of Adult Reading); (3) HIV-seropositive (with documentation from medical records) or seronegative for HIV (confirmed by an HIV ELISA blood test if screened positive with ClearView® COMPLETE HIV-1/2 Test); (4) HIV+ participants had to be stable on an antiretroviral regimen for 6-months or would remain without antiretroviral treatment during the study. The exclusions criteria for all participants were: (1) history of any co-morbid and confounding psychiatric illness(es) unrelated to HIV-infection; (2) any confounding neurological disorder (e.g., multiple sclerosis, Parkinson's disease, non-HIV brain infections, neoplasms, cerebral palsy, or significant head trauma with loss of consciousness >30 min); (3) significantly abnormal screening laboratory tests (>2 SD) indicating a chronic medical condition that might affect brain function; (4) pregnancy (verified by urine pregnancy test in women of child bearing age); (5) other contraindications for MR studies, such as metallic or electronic implants in the body (e.g. pacemaker, surgical clips, pumps, etc.), or severe claustrophobia.
All 66 participants completed the detailed clinical and neuropsychological evaluations, the Patient Reported Outcome Measurement Information System (PROMIS) online pain questionnaire (Apkarian et al. 2005) , and had good quality brain MRI scans.
Image Acquisition for Structural MRI All MRI studies were performed on a research-dedicated 3 Tesla Siemens TIM Trio scanner (VB17, Siemens Medical Solutions, Erlangen, Germany) using a 12-channel phase-array head coil. Following a localizer scan, a 3D magnetization-prepared rapid gradient echo (MP-RAGE) scan was performed (sagittal, TE/TR/ TI = 4.47 ms/2.2 s/1 s, 12°flip angle, FOV = 320 mm, 1.0 × 1.0 × 1.0 mm resolution, 192 slices, ipat mode GRAPPA, acceleration factor = 2, slice thickness = 1 mm). Next, a 3D-T2-weighted sequence (FLAIR) was acquired (transversal, TE/TR/TI = 84/9100/2500 ms, slice thickness 3.0 mm). Although all participants had repeat structural scans after the cognitive training for the parent study, only the baseline scans prior to any intervention were included in the current study. All scans were reviewed by the study physicians to screen for possible brain lesions or structural abnormalities. All subjects had good quality scans that passed the quality control criteria.
Image Processing and Analysis All MR scans were processed using the surface-based method in FreeSurfer 5.3 (Dale et al. 1999) . The program automatically reconstructed and labeled 40 subcortical and 70 cortical regions in each hemisphere. Brain structures were automatically-registered using an existing brain template [Montreal Neurological Institute (MNI)] prior to segmentation and after extraction from the skull. All regions were visually inspected to ensure accurate segmentation. Manual editing of the volumetric segmentation was performed only if gross misalignment was detected on visual inspection. Editing was performed blinded to the subjects' HIV-serostatus or pain scale severity in order to minimize bias. Regional cortical area, cortical thickness, and subcortical volume for the anatomic regions of interest (ROIs) were automatically determined in each hemisphere.
Seven cortical and five subcortical ROIs from each hemisphere were selected for this study based on previous brain imaging studies on pain (Apkarian et al. 2005; Melzack 2005; Tracey and Mantyh 2007; Schweinhardt and Bushnell 2010; Oertel et al. 2012; Hashmi et al. 2013) . These ROIs are part of the pain matrix, which includes the prefrontal cortex (PFC), cingulate cortex (CC), somatosensory cortex (SSC), posterior parietal cortex (PPC), insula, basal ganglia, thalamus, hippocampus, amygdala, and brainstem ( Fig. 1) . The cortical ROIs selected for the current study included anterior cingulate cortex (ACC), postcentral and supramarginal regions of the SSC, pars triangularis of the inferior frontal gyrus and orbitofrontal cortex (OFC) of the PFC, insula, and precuneus of the PPC. The subcortical ROIs included subcomponents of the basal ganglia (caudate, putamen, pallidum and accumbens) and thalamus.
Pain Measures All participants completed the Patient Reported Outcomes Measurement Information System (PROMIS®) pain questionnaire (Apkarian et al. 2005) at the time of enrollment. The pain questionnaire comprises 10 questions on global health status (PROMIS SF v1.1 Global Health), 3 questions on pain intensity (PROMIS Scale v1.0 Pain Intensity 3a), 4 to 12 computer adaptive test (CAT) questions on pain interference (PROMIS Bank v1.1 Pain Interference), and 4 to 12 CAT questions on pain behavior (PROMIS Bank v1.0 Pain Behavior). Pain intensity questions determined Bhow much it hurts^, pain interference defined Bhow the pain affected the participant's daily life^, and pain behavior evaluated Bhow the participant manifested his/her pain^. All scores for each of the 3 pain domains and for the global health status assessment were normalized using the transmutation table provided by PROMIS which accounted for age, sex, race, and education level ). The normalized data were expressed as T-scores. Individuals with T-scores ≥60 for pain intensity, pain interference and pain behavior were considered above population average for pain severity, and those with T-scores ≤40, were below population average. The global health status consisted of 2 domains, physical health and mental health. Individuals who had Tscores of ≥60 were one standard deviation healthier than the general population, and those that had T-scores ≤40 1 standard deviation less healthy than the general population.
Statistical Analysis Statistical analyses were performed with R studio-Version 0.99.335; (RStudioTeam 2015) or the SAS Enterprise Guide 7.1 software. Group differences in age, sex distribution, race distribution and other participant characteristics were analyzed using Chi-square tests for categorical variables, and two-sample T-tests for continuous variables. All brain morphometric analyses of volume and surface area used estimated total intracranial volume (eTIV) as a covariate to correct for the total volume of the cranium (Buckner et al. 2004; Malone et al. 2015; Sargolzaei et al. 2015) . Since cortical thickness does not scale with head size (Barnes et al. 2010) , only age and sex were used as covariates for cortical thickness analysis.
One-way analysis of covariance [ANCOVA] was used to determine the HIV+ status effect on pain measures (Aim 1) and brain morphometry (Aim 2). Two-way ANCOVAs further evaluated 1) the main and interactive effects of pain measures and HIV status on brain morphometric measures (cortical area, cortical thickness, and subcortical volume) (Aim 3), and 2) the main and additive effects of pain scores and HIV status on global mental health outcomes (Aim 4). Post hoc analyses using linear regressions were performed across both subject groups for the measures that did not show interactive effects. Normality was checked using QQ-plots. All results with Pvalues < 0.05 were considered significant and P-values between 0.05-0.09 were considered trends. Bonferroni correction was not applied because the measures selected were based on a priori hypotheses derived from prior publications.
Results
Participant Characteristics (Table 1) The two subject groups (35 HIV and 31 SN controls) had similar mean age, sex proportion, race distribution, mean years of education, Hollingshead Index of Social Position (ISP), and Center for Epidemiologic Studies-Depression Scale (CES-D) scores. Only a few HIV (n = 3, 8.8%) and SN participants (n = 5, 16.1%) had frequent headaches. However, similar to previous studies (Schütz and RobinsonPapp 2013; Ekenze et al. 2014) , many more HIV+ individuals had distal neuropathy (56%) than SN controls (26%). Of the 12 participants taking pain medications during the study, 7 used opioids (oxycodone, hydrocodone), or drugs that convert to opioid (2 used tramadol), 7 also used nonsteriodal antiinflammatory drugs (NSAIDS) (aspirin, ibuprofen, naproxen), and 1 used a muscle relaxant (carisoprodol), Table 1 .
Pain Measures
HIV+ participants scored higher than SN controls on all three pain measures (pain intensity, pain interference, and pain behavior, Table 2 ). Correlation analysis between these pain measures and HIV+ participants' characteristics (age, HIV disease duration, CD4 count, and viral load) showed significant positive correlations only between duration of HIV+ diagnosis and two pain measures: pain intensity (r = +0.37, p = 0.03) and pain behavior (r = +0.39, p = 0.02).
Brain Morphometric Measures
Cortical and subcortical morphometry measures were compared between HIV+ and SN subjects, using a one-way ANCOVA. Independent of pain status, HIV+ individuals had smaller cortical areas in bilateral pars triangularis (left: −9.2%. p = 0.007, right: −6.1%. p = 0.04) and right ACC (−6.0%, p = 0.03) (Fig. 2a) , and smaller volumes in bilateral thalamus (left: −7.9%, p = 0.002; right: −7.3%, p = 0.003) and right putamen (−7.3%, p = 0.01) (Fig. 2b) .
Brain regions that showed significant morphometric abnormalities in HIV+ individuals belonged to the affectivemotivational component of the pain matrix (Price 1992; Treede et al. 1999; Price 2000; Johansen et al. 2001; Apkarian et al. 2005; Oertel et al. 2012; Hashmi et al. 2013) .
Relationships between Brain Morphometry and Pain Measures
We also explored possible group differences in the relationship between brain morphometry and pain measures. Only three brain regions (left supramarginal area, left putamen volume and right pallidum volume) showed significant pain effects on the two-way ANCOVAs. However, the pain effects were different between HIV+ individuals and SN controls, showing higher pain scores with larger cortical area and subcortical volumes in HIV+ individuals, but smaller brain measures in SN controls. Hence, these interactive effects are described and illustrated below.
Interactions between Pain Assessments and HIV Status on Brain Morphometry

Pain Intensity
Pain intensity-by-HIV status interactions were found in the left supramarginal area (Fig. 3a) , right pallidum volume (Fig. 3b) , and bilateral putamen volumes (Fig. 3b) . For all of these regions, HIV+ individuals with higher pain intensity had larger cortical areas and subcortical volumes, whereas SN controls with higher pain intensity had smaller cortical areas and subcortical volumes.
Pain Interference
Pain interference-by-HIV serostatus interactions on brain morphometry were found in several cortical and subcortical regions (Fig. 4) . HIV+ individuals with higher pain interference scores had smaller cortical areas in left pars triangularis, thinner right OFC, and thinner right ACC, while SN controls with higher pain interference scores had larger areas and thicker cortices in these same brain regions (Fig. 4a) . In contrast, higher pain interference scores were associated with larger cortical areas in the left supramarginal and left OFC region in HIV+ individuals but with smaller areas in the SN controls (Fig. 4a) .
Amongst the subcortical ROIs, a pain interference-by-HIV serostatus interaction was found only in the right putamen. Higher pain interference scores were associated with larger right putamen volumes in HIV subjects but smaller right putamen volumes in SN controls (Fig. 4b) .
Pain Behavior
The surface area of the left supramarginal region (Fig. 5a) and volumes of the subcortical regions (bilateral putamen, right pallidum, and left accumbens, Fig. 5b ) showed pain behavior- by-HIV serostatus interactions. For all of these interactions, higher pain behavior scores were associated with larger brain areas in the cortical regions and volumes in the subcortical regions in HIV+ participants, but smaller brain measures in SN controls. In contrast, the opposite relationships were observed in the right OFC and right ACC thickness (Fig. 5c) , in which pain behavior scores correlated negatively with thickness in HIV+ participants but positively in SN controls.
Pain Measures and Global Health Status (Fig. 6)
On two-way ANCOVA, main effects of all pain measures (Tscores of pain intensity, pain interference and pain behavior) were found on mental and physical health scores regardless of HIV serostatus. Individuals with higher pain intensity, pain interference, and pain behavior scores consistently had poorer mental and physical health, regardless of HIV serostatus. The strongest associations were found between physical health score and pain Interference (r = −0.7, p < 0.001) or pain intensity (r = −0.68, p < 0.001). No pain-by-HIV serostatus interaction or HIV-serostatus effects on these global health measures were observed (Fig. 6 ).
Discussion
This is the first study to use PROMIS® pain questionnaires to evaluate pain symptoms in HIV+ individuals, and determine whether their pain symptoms are related to morphometric brain abnormalities within the pain matrix. There were four major findings. 1) HIV+ individuals had higher pain scores than SN controls which might have resulted from direct effects of the virus or reactive inflammation causing painful nerve damage (Kemp et al. 2008; Grovit-Ferbas and Harris-White 2010; Hao 2013) had smaller volumes than SN controls in the right putamen and bilateral thalamus. P-values for group differences are from one-way ANCOVA (co-varied for age, sex and eTIV for cortical area and subcortical volumes; co-varied for age and sex for cortical thickness) triangularis, right ACC and right putamen). These alterations might have resulted from neuronal degeneration mediated by chronic HIV-associated neuroinflammation (Adle-Biassette et al. 1999; Kaul et al. 2001; Corasaniti et al. 2003; Hong and Banks 2015) . 3) In most brain regions, larger volumes and thinner cortices were associated with higher pain measures in HIV+ participants, but lower pain measures in SN controls. These opposite associations suggest both acute and chronic inflammation in the HIV+ participants, with brain swelling and neurodegeneration, but primarily neuronal loss from chronic neuroinflammation in SN controls. 4) Regardless of HIV-serostatus, participants with lower pain scores had better global health status (physical and mental), suggesting that pain symptoms had greater impact on an individual's quality of life, with or without a concomitant chronic disease (Breitbart et al. 1996; Merlin et al. 2013; Uebelacker et al. 2015; Mann et al. 2016) .
Pain in HIV+ Individuals
The prevalence of distal neuropathy in our HIV+ participants (56%) was consistent with other studies in adult HIV+ individuals (42% -57%) (Ellis et al. 2010; Ekenze et al. 2014; Phillips et al. 2014) . The higher pain severity on PROMIS® in our HIV+ compared to SN individuals was consistent with prior findings using other instruments (i.e. Brief Pain Inventory (Breitbart et al. 1996; Merlin et al. 2012; Phillips et al. 2014; Uebelacker et al. 2015) , Wisconsin Brief Pain Questionnaire (Mphahlele et al. 2012) , Numerical Rating Scale , or McGill Pain Questionnaire (Serchuck et al. 2010; Parker et al. 2014) ). Although our HIV+ participants were stable clinically, more prevalent and pronounced pain symptoms were still present, some from painful neuropathy caused by direct effects of the virus, or persistent side effects of past medications (i.e. didanosine or stavudine) (Kemp et al. 2008; Grovit-Ferbas and Harris-White 2010; Hao 2013; Uebelacker et al. 2015) . The multicenter CNS Antiretroviral Therapy Effects Research (CHARTER) cohort demonstrated that past antiretroviral medications can influence pain symptoms in HIV patients (Malvar et al. 2015) . Moreover, our HIV+ participants as a group had been diagnosed for~16 years, and those with longer HIV disease duration also had more pain symptoms, Fig. 3 HIV+ individuals and SN controls showed opposite relationships between pain intensity and brain morphometry in the L supramarginal area, bilateral putamen volumes, and R pallidum volume. These graphs show that HIV+ individuals with higher pain intensity tended to have bigger cortical area in the L supramarginal region and larger subcortical volume in the R pallidum and bilateral putamen, while SN controls with higher pain intensity scores had smaller left supramarginal area, and smaller volumes in the right pallidum and bilateral putamen consistent with reports indicating prolonged HIV-infection may increase risk of acquiring painful co-morbidities (i.e. neuropathy) (Stewart et al. 1996; Glare 2001; Lawson et al. 2014) . Pain experienced by HIV+ individuals is typically chronic pain from either peripheral or central sensitization (Carr 2004; Nair et al. 2009 ). Ongoing HIV-infection may trigger local tissue inflammation leading to hypersensitization of peripheral nervous system receptors, while chronic infection (e.g., HIV or other co-occurring viruses) may further lead to central sensitization. With central sensitization, prolonged exposure of brain cells to inflammatory neurotransmitters (e.g., glutamate), neuromodulators (e.g., BDNF), and immune mediators (e.g., cytokines or chemokines), may trigger hyperactivity of postsynaptic nociceptive neurons (Merlin 2015) .
Brain Morphometry in HIV+ Individuals
The brain atrophy in our HIV+ patients, regardless of pain symptoms, is consistent with previous findings (Becker et al. 2011; Sarma et al. 2014 ). Brain volume loss was thought to result from the direct neurotoxic effects of HIV viral proteins, or indirect effects of HIV-mediated glial inflammatory responses; both processes may lead to neurodegeneration (Wiley et al. 1991; Masliah et al. 1992; Adle-Biassette et al. 1995) .
Smaller areas in the pars triangularis and ACC in HIV+ patients compared to SN controls are consistent with prior findings of smaller than normal gray matter volumes in the frontal and cingulate cortices (Fischer et al. 1999; Küper et al. 2011; Wang et al. 2016) . Similarly, subcortical atrophy in the thalamus and putamen of our HIV+ participants is also expected (Becker et al. 2011; Chang et al. 2011; Wade et al. 2015) , and likely reflects neurodegeneration from HIV-induced neurotoxicity, since subcortical regions typically showed the highest viral burden (Ranki et al. 1995; Gray et al. 2001) .
Furthermore, compared to SN controls, HIV+ participants had more brain atrophy and higher scores on the affective component of pain measures. These findings suggest that abnormalities in brain morphometry within the 
Pain and Brain Morphology
The few brain regions that showed associations with pain effects showed opposite effects between HIV+ participants and SN controls, suggesting that pain related-brain alterations might have resulted from different or mixed types of pain processes, such as acute and chronic pain (Borsook et al. 2013) . Patients with acute pain showed larger brain volumes (Cleary and Heinricher 2013) , likely due to cellular swelling and edema from ongoing acute inflammation Freund et al. 2011; Ceko et al. 2013; Mole et al. 2014) . Similarly, healthy individuals who underwent repeated painful stimulation showed enlarged brain volumes (Teutsch et al. 2008) . In contrast, chronic pain patients tended to have smaller brain volumes (Robinson et al. 2011) , likely as a consequence of neuronal loss, maladaptive plasticity, or retrograde neuronal degeneration in response to tissue injury or prolonged inflammation Freund et al. 2011; Ceko et al. 2013; Mole et al. 2014 ).
Brain Morphologic Abnormalities in HIV+ Individuals with Pain
Our HIV+ individuals showed evidence of both acute and chronic pain since those with higher pain scores had larger cortical areas and subcortical volumes, as well as thinner cortices. The acute inflammation may be due to the various neurotoxic processes that led to brain swelling, while chronic inflammation in response to ongoing HIV infection may lead to neuronal loss and neurodegeneration (Rodriguez-Raecke et al. 2009; Baliki et al. 2011) .
In healthy individuals, pain sensitivity positively correlated with thicker cortical gray matter in brain regions that are implicated in sensory, affective and cognitive aspects of pain (Erpelding et al. 2012) . In contrast, our HIV+ individuals with higher pain behavior score tend to have: (1) bigger cortical area in the L supramarginal region and L medial OFC; (2) thinner cortex in the R lateral OFC; and (3) larger subcortical volumes in the R pallidum, L accumbens and, bilateral putamen, but SN controls showed the opposite relationship in these brain measures higher pain scores showed thinner cortices in right OFC and right ACC (affective components of pain matrix), which suggests that acute pain may also lead to brain injury involved in Bpsychological pain^in these individuals. Direct neuronal damage from HIV may lead to functional loss and tissue shrinkage (Gustin et al. 2011) , while chronic ongoing inflammation may lead to indirect central and peripheral sensitization from repeated neuronal stimulation or prolonged exposure of neuronal cells to neurotoxic inflammatory mediators (Ji et al. 2014) .
Cortical thickness may provide a good surrogate measure for overall pain dysfunction in those with chronic pain (Erpelding et al. 2012; Frøkjaer et al. 2012; Desouza et al. 2013) . The thinner cortices in regions involved in the affective pain component, such as OFC and ACC, in HIV+ individuals with higher pain interference and pain behavior scores also may lead to an impaired pain response (Lloyd et al. 2016) . Similar correlations between cortical thickness and pain interference and behavior scores were found in chronic pain patients with interruptions in the pain modulation network, which led to increased pain perception and impaired pain aversion response (Moont et al. 2011; Desouza et al. 2013 ). Other studies, using different instruments to measure pain, also found more affective symptoms and distress in HIV+ individuals (Price 1992 (Price , 2000 Evans et al. 2003) . Additionally, using a conditioned pain paradigm and chemically-induced lesions in the ACC of rodents, atrophy from neuronal damage in the ACC was associated with higher pain interference and pain behavior scores, but reduced pain avoidance and pain aversive behavior (Johansen et al. 2001; Qu et al. 2011; Yan et al. 2012; Barthas et al. 2015) .
Physical and Mental Health of HIV+ Individuals with Pain
We hypothesized that the dual insults from pain and HIV infection on the brain would lead to lower global health status (n = 21,133 + 967; mean age 48.2; 52% female; 82% white, 9% black, 8% multiracial, 1% other; 3% < HS, 16% HS, 39% some college, 24% college, 19% post-baccalaureate) (mental and physical health scores) in HIV+ participants relative to the SN individuals. However, in this clinically-stabled group of HIV+ participants, we did not find significant associations between HIV disease and global health status, or significant pain-by-HIV disease interactions on global health status. Across both groups, individuals with higher pain scores consistently had lower physical and mental health scores, suggesting that only pain, but not HIV-seropositivity, contributed to the poorer quality of life. This finding validates prior reports that HIV+ patients with well-controlled pain had better quality of life (Merlin et al. 2013; Uebelacker et al. 2015) . Therefore, better and more aggressive pain management strategies are important for the well-being of HIV+ individuals with pain.
This study has several limitations. Since this is a crosssectional study, the associations between pain, HIV disease and brain abnormalities do not imply causality. Longitudinal evaluations or treatment studies are needed to further delineate these relationships. Although the pain assessments from PROMIS® showed robust group effects, the sample size is moderate for a morphometry study. Future studies with larger sample sizes are needed to validate brain morphometry as biomarkers for pain measures in HIV-infected individuals. Since the PROMIS® pain questionnaire did not assess specific pain characteristics, such as the type, location, or duration of pain symptoms, further research correlating these characteristics with abnormal brain measures is needed.
In summary, many of our HIV+ individuals manifest symptoms of pain despite well-controlled viremia. In the HIV+ participants, the association between higher pain scores and larger cortical areas and subcortical volumes suggest ongoing acute inflammation, while the pain-severity-associated thinner cortices suggest concomitant chronic inflammation as a consequence of ongoing HIV disease. In SN controls, the painseverity-associated smaller brain volumes also suggest neurodegeneration from chronic inflammation.
The opposite relationships between morphometry and pain scores in HIV+ individuals and SN controls suggest that the pain response in HIV+ subjects is altered. These abnormal pain-associated brain regions in HIV+ participants involved the affective component of the pain matrix, which further suggests a psychological influence on their pain response. Therefore, pain management for HIV+ patients should include treatment of their affective symptoms. Lastly, the association of low pain scores in participants with better global health further demonstrates the importance of adequate pain treatment for better quality of life in all participants.
